| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The molecular target is hemoglobin (Hb). ITPP binds specifically to deoxyhemoglobin at the 2,3-DPG binding pocket, stabilizing the T-state (tense, low-affinity conformation). This increases oxygen release to tissues under hypoxic conditions, enhancing tissue oxygenation without affecting blood flow.
|
|---|---|
| ln Vitro |
In vitro, ITPP increases the p50 (partial pressure of oxygen at 50% hemoglobin saturation) of human red blood cells. At 1-5 mM, it shifts the oxygen dissociation curve rightward by 5-15 mmHg. It does not alter erythrocyte morphology, ATP levels, or cause hemolysis at therapeutic concentrations.
|
| ln Vivo |
In vivo, ITPP has shown efficacy in mouse models of cancer (e.g., breast, colon, glioma) by increasing tumor oxygenation and reducing hypoxia-induced resistance to chemotherapy and radiotherapy. It also improves exercise capacity in normal mice and reduces ischemic damage in stroke models.
|
| Enzyme Assay |
Standard protocol: Hemoglobin oxygen binding is measured using a Hemox Analyzer. Human whole blood or purified hemoglobin is incubated with ITPP hexa-triethylamine (10-1000 microM) for 15 minutes at 37degC. The sample is then oxygenated and deoxygenated by varying pO2, and the change in absorbance at specific wavelengths is recorded to generate the dissociation curve.
|
| Cell Assay |
Standard cellular assays: Erythrocytes are incubated with ITPP for 1-4 hours. Hemoglobin oxygen affinity is measured using a blood gas analyzer or by spectrophotometric methods. Cell viability is assessed by flow cytometry with Annexin V/PI staining. No cytotoxicity is expected in nucleated cell lines as ITPP does not enter cells.
|
| Animal Protocol |
In vivo efficacy: Tumor-bearing mice (e.g., 4T1 breast cancer) are treated intraperitoneally or intravenously with ITPP hexa-triethylamine (e.g., 1-2 g/kg) twice weekly. Tumor pO2 is measured by electron paramagnetic resonance oximetry or hypoxia probe (pimonidazole). Tumor growth delay and response to radiation/chemotherapy are assessed.
|
| ADME/Pharmacokinetics |
ITPP has a prolonged half-life in plasma (estimated 10-20 hours in mice) due to its high water solubility and resistance to metabolic degradation. The hexa-triethylamine salt form improves solubility and stability. ITPP does not cross the blood-brain barrier or enter cells readily.
|
| Toxicity/Toxicokinetics |
Toxicology: ITPP is remarkably non-toxic even at high doses. In mice, LD50 > 5 g/kg. No significant changes in blood cell counts, liver enzymes, or kidney function were observed in subchronic studies. The triethylamine counterion is present in stoichiometric amounts and is considered safe at administered doses.
|
| References |
[1]. Fylaktakidou KC, et al. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1605-8.
|
| Additional Infomation |
ITPP has been investigated in preclinical studies and early phase clinical trials (Phase I/II) for cancer treatment as an adjunct to radio/chemotherapy. It has orphan drug status in some jurisdictions. No full approval as of 2026. The hexa-triethylamine salt is a research-grade formulation.
|
| CAS # |
851086-77-6
|
|---|---|
| PubChem CID |
168446886
|
| Appearance |
Colorless to light yellow oil
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
27
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
75
|
| Complexity |
932
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 125 mg/mL (103.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
